Contact us on +44 (0)1270 270010 | info@boydconsultants.com

Early access continues during the coronavirus pandemic

Early access continues during the coronavirus pandemic
April 15, 2021 SueCarr

The MHRA is committed to speeding up access to innovative new medicines for patients. The Early Access to Medicines Scheme (EAMS) gives patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need. The scheme has remained fully operational throughout the coronavirus (COVID-19) pandemic, ensuring that patients with serious conditions can still be offered new treatment options for their conditions.

Read more.